IRCT20201104049257N1 IRCT 2021-05-10 Tehran University of Medical Sciences Rivastigmine effect on mild cognitive impairment patients decision making Evaluation of the effect of rivastigmine on decision making in mild cognitive impairment (MCI) patients by Cambridge Neuropsychological Test Automated Battery (CANTAB) 2021-04-21 anticipated 40 Complete https://irct.ir/trial/52063 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patient randomization is done online (sealedenvelope.com). Using 4 blocks (Permuted balance Block) for a total of 72 patients with a 1: 1 allocation ratio, this random chain and anonymous codes consisting of 2 letters and a number will be made. When random assignment is made, four letters (corresponding to the first two letters of the first name and the first two letters of the last name) are added to these codes. On the package of drugs, the research label and the relevant codes are already inserted according to the produced sequence, Blinding description: This study is designed to be double-blind. Research labeling will be done on two products. All the drugs used in the study are in completely opaque packages and their lids will be packaged with a disposable label. This package contains the corresponding randomization code. In this way, patients and physicians evaluating the clinical outcome will not be aware of the allocation of patients in treatment groups. Finally, all data will be coded for analysis. 3 Mild Cognitive Impairment (MCI). Intervention 1: Intervention group: Pack of 30 oral capsules of rivastigmine (hydrogen titrate) 3 mg Hakim Pharmaceutical Company twice a day. Intervention 2: Control group: Pack of 30 oral capsules of rivastigmine (hydrogen titrate) 3 mg Hakim Pharmaceutical Company twice a day. No - There is not a plan to make this available Justification or reason for not sharing IPD is due to confidentiality